key: cord-0043372-hvqiiz64
authors: Swanson, Scott J.
title: Commentary: Primum non nocere
date: 2020-05-12
journal: J Thorac Cardiovasc Surg
DOI: 10.1016/j.jtcvs.2020.04.143
sha: 9d8d4ce9f8f0140ea1242d3f57b1894ac1aaea25
doc_id: 43372
cord_uid: hvqiiz64

nan

Thoracic surgeons need to factor in a new enemy, an invisible virus that can be difficult to detect but wreaks havoc and death for our patients. Until we have a more complete ability to detect which of our surgical patients may be harboring the COVID-19 virus or have immunity, we should be extremely careful about proceeding with any non-emergent surgery of the chest. The article in the Journal by Huang and his colleagues from Wuhan demonstrate the insidious and devastating nature of the COVID virus in otherwise healthy patients who undergo a pulmonary lobectomy 1 . Other issues for surgeons to consider are the fact that many patients in our hospitals in the near term will have this virus making transmission to our post-operative patients a potential problem despite all conceivable precautions and if our patients have a post-operative complication that requires an ICU stay or re-intubation it is possible the hospital will not have the resources necessary to care for this patient. As the patient's doctor and surgeon we must weigh the variables and make the best recommendation for the patient since it is very difficult for a patient with cancer to put all of this into perspective. Most thoracic cancers that we operate on can be deferred for a month or so without significant consequence. If the time period will be much longer then consideration for alternative treatments to bide time until resection or in place of resection should be considered. Regardless, a low risk patient dying of an overwhelming and currently untreatable infection with a relatively high prevalence will be hard for any of us to rationalize.

Clinical course of patients infected with SARS-CoV-2 soon after thoracoscopic lung surgery